Redefining ADC Payload Design Through Targeted Biology to Expand the Therapeutic Window
- Demonstrate how a non-cytotoxic, mechanism-selective payload approach can address key limitations of traditional cytotoxic ADCs by improving tolerability while maintaining therapeutic activity
- Explore the rationale for targeting TGF-β biology to overcome immunosuppression, resistance mechanisms, and fibrotic disease progression across a range of disease settings
- Highlight opportunities to expand ADC applications beyond conventional oncology paradigms by leveraging targeted biological modulation to improve therapeutic index, unlock novel indications, and create differentiated treatment strategies